Abstract
Objective. We sought to analyze the results of topical treatment with a mouthwash of 0.05% clobetasol
in aqueous solution in 30 patients with severe oral erosive lesions. Study Design. Over a 48-week period, we evaluated the evolution of pain, ulcerations, atrophy,
and interference of the disease in the patient's daily life, classifying the response
as complete (100% remission/recovery), excellent (75%), good (50%), poor (<50%), or failed. Results. The pain and ulceration totally disappeared in 93.3% of cases and 90% reported a
full recovery in their daily life activities. Atrophy response was complete in 28.5%,
excellent in 60.7%, and good in 3.5%. Two patients showed no response to the treatment.
Five patients suffered mild adverse effects (moon face and hirsutism) between week
4 and week 6 of treatment, which were speedily reversed by reducing the frequency
of mouthwash. Conclusions. Clobetasol mouthwash is a safe and efficacious option for the treatment of severe
oral erosive lesions. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:264-70)
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Oral lichen planus: topical and systemic therapy.Semin Cutan Med Surg. 1997; 16: 295-300
- A prospective follow up study of 570 patients with oral lichen planus: persistence, remission, and malignant association.Oral Surg Oral Med Oral Pathol. 1985; 60: 30-34
- A prospective study of findings and management in 214 patients with oral lichen planus.Oral Surg Oral Med Oral Pathol. 1991; 72: 665-670
- An open study using clobetasol propionate (Temovate) in orabase for the treatment of oral vesiculoerosive diseases.Oral Surg Oral Med Oral Pathol. 1991; 71: 283-287
- Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases.Oral Surg Oral Med Oral Pathol. 1991; 71: 293-297
- Double-blind trial of 0.05% clobetasol propionate ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases.Oral Surg Oral Med Oral Pathol. 1994; 77: 598-604
- Method for comparing percutaneous absorption of steroids.Arch Dermatol. 1962; 86: 808-810
- A comparison of clobetasol propionate 0.05% ointment and optimized betamethasone dipropionate 0.05% ointment in the treatment of psoriasis.Cutis. 1986; 37: 213-220
- Temovate (clobetasol dipropionate/Glaxo) product monograph. Clinical and laboratory studies. : Glaxo Inc, Research Triangle Park, NC1983: 7
- Double-blind clinical trial of 0.05% clobetasol propionate ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with vesiculoerosive diseases.Oral Surg Oral Med Oral Pathol. 1994; 77: 598-604
- Effect of dental plaque control on gingival lichen planus.Oral Surg Oral Med Oral Pathol. 1990; 69: 585-590
- Adverse side effects associated with prednisone in the treatment of patients with oral inflammatory ulcerative diseases.J Am Dent Assoc. 1984; 109: 269-270
- Alendronate-related oral mucosa ulcerations.J Oral Pathol Med. 2000; 29: 514-518
- Lichen planus and hepatitis C virus-related chronic active hepatitis.Arch Dermatol. 1966; 130: 73-76
- Chronic active hepatitis and lichen planus.Acta Dermato-Venerol (Stockholm). 1982; 62: 351-352
- Oral lichen planus and chronic liver disease: a clinical and morphometric study of the oral lesions in relation to transaminase elevation.Oral Surg Oral Med Oral Pathol. 1994; 78: 337-342
- Lichen planus, chronic liver diseases, and immunologic involvement.Arch Dermatol Res. 1988; 280: 555-560
- Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisolone.J Clin Endocrinol Metab. 1981; 53: 1076-1080
Article info
Publication history
Accepted:
September 20,
2001
Received in revised form:
August 9,
2001
Received:
July 3,
2001
Footnotes
*Reprint requests: Miguel Angel Gonzalez Moles, MD, PhD, Medicina Oral Facultad de Odontologia, Colegio Maximo s/n Campus de Cartuja, Universidad de Granada,E-18071-GRANADA, Spain, [email protected]
Identification
Copyright
© 2002 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
